These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19671771)

  • 1. Numbers needed to decide.
    Woloshin S; Schwartz LM
    J Natl Cancer Inst; 2009 Sep; 101(17):1163-5. PubMed ID: 19671771
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.
    Brenner H; Heywang-Köbrunner S; Becker N
    J Natl Cancer Inst; 2010 Mar; 102(5):356; author reply 356-7. PubMed ID: 20075365
    [No Abstract]   [Full Text] [Related]  

  • 3. Public knowledge of benefits of breast and prostate cancer screening in Europe.
    Gigerenzer G; Mata J; Frank R
    J Natl Cancer Inst; 2009 Sep; 101(17):1216-20. PubMed ID: 19671770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer screening gets risk-specific.
    Peres J
    J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
    [No Abstract]   [Full Text] [Related]  

  • 5. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 7. The science and art of prostate cancer screening.
    Yao SL; Lu-Yao GL
    J Natl Cancer Inst; 2011 Mar; 103(6):450-1. PubMed ID: 21350220
    [No Abstract]   [Full Text] [Related]  

  • 8. Patients Present with More Advanced Prostate Cancer since the USPSTF Screening Recommendations.
    Barry MJ; Nelson JB
    J Urol; 2015 Dec; 194(6):1534-6. PubMed ID: 26384450
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigation momentum: the relentless pursuit to resolve uncertainty.
    Sah S; Elias P; Ariely D
    JAMA Intern Med; 2013 May; 173(10):932-3. PubMed ID: 23588200
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 11. Inadvisable breast and prostate cancer screenings in the USA.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e92. PubMed ID: 26831288
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate-specific antigen testing in france.
    Braillon A
    JAMA Intern Med; 2013 Nov; 173(21):2014. PubMed ID: 24276059
    [No Abstract]   [Full Text] [Related]  

  • 13. [Counseling for cancer screening. Offer the facts instead of false promises].
    Klein F
    MMW Fortschr Med; 2010 Nov; 152(47):14-7. PubMed ID: 21226371
    [No Abstract]   [Full Text] [Related]  

  • 14. Communicating benefits and risks of screening for prostate, colon, and breast cancer.
    Barrett B; McKenna P
    Fam Med; 2011 Apr; 43(4):248-53. PubMed ID: 21499997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 16. Why I will continue to screen prostate-specific antigen for myself and other appropriate men.
    Keller DL
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394929
    [No Abstract]   [Full Text] [Related]  

  • 17. Why I will continue to screen prostate-specific antigen for myself and other appropriate men--reply.
    Katz MH
    JAMA Intern Med; 2014 Jan; 174(1):164. PubMed ID: 24394931
    [No Abstract]   [Full Text] [Related]  

  • 18. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 19. Organised mammographic screening--more benefits than harms.
    Hofvind S
    Tidsskr Nor Laegeforen; 2013 Mar; 133(6):619-20. PubMed ID: 23552154
    [No Abstract]   [Full Text] [Related]  

  • 20. Can we stop ordering prostate-specific antigen screening tests?
    Katz MH
    JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.